{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:12:59Z","timestamp":1793038379360,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of antipsychotic medications, including first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs), during pregnancy has risen substantially. However, concerns remain regarding their potential metabolic effects, especially the risk of gestational diabetes mellitus (GDM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of observational studies published up to 2025 that examined the association between maternal exposure to antipsychotics or antidepressants and the risk of GDM. Data were extracted independently by two reviewers, quality was assessed using the Newcastle\u2013Ottawa Scale, and pooled relative risks (RRs) were calculated using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We selected seventeen eligible studies, including large registry-based cohorts and prospective investigations across multiple countries. Pooled analysis demonstrated that maternal exposure to SGAs was significantly associated with an increased risk of GDM (RR = 1.59; 95% CI: 1.24\u20131.94), whereas FGAs showed no significant association (RR = 1.31; 95% CI: 0.29\u20132.32). The risk appeared greatest among women with continuous or multi-trimester exposure, particularly when exposure extended from first trimester into the third trimester. Funnel plot and Egger test showed no publication bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The higher risk of GDM seen with antipsychotic use was mainly linked to SGAs, while FGAs did not show the same effect. These findings emphasize the need to tailor treatment plans, closely monitor blood sugar levels, and involve a team of healthcare professionals when caring for pregnant women who require psychotropic medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1710101","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:10:20Z","timestamp":1770729020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of antipsychotic consumption during pregnancy on risk of gestational diabetes development: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingna","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1158969","article-title":"Effect of gestational diabetes mellitus on pregnancy outcomes among younger and older women and its additive interaction with advanced maternal age","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fgwh.2025.1528661","article-title":"Global, regional, and national burden of diabetes in women of childbearing age, 1990-2021: A systematic analysis from the Global Burden of Disease Study 2021","volume":"6","author":"Guo","year":"2025","journal-title":"Front Global Women\u2019s Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.1079","article-title":"Antidepressants, antipsychotics, and mood stabilizers in pregnancy: what do we know and how should we treat pregnant women with depression","volume":"109","author":"Ornoy","year":"2017","journal-title":"Birth defects Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.1870","article-title":"Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects","volume":"69","author":"Bod\u00e9n","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1017\/S003329171900401X","article-title":"The use of antipsychotic agents during pregnancy and the risk of gestational diabetes mellitus: a systematic review and meta-analysis","volume":"51","author":"Wang","year":"2021","journal-title":"psychol Med"},{"key":"B6","article-title":"Antipsychotic exposure in pregnancy and the risk of gestational diabetes: a systematic review and meta-analysis","volume":"46","author":"Kucukgoncu","year":"2020","journal-title":"Schizophr Bulletin"},{"key":"B7","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"bmj"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0406","article-title":"Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study","volume":"66","author":"McKenna","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0b013e318172b8d5","article-title":"Maternal use of antipsychotics in early pregnancy and delivery outcome","volume":"28","author":"Reis","year":"2008","journal-title":"J Clin psychopharmacology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-008-0044-3","article-title":"Atypical antipsychotic use in pregnancy: a retrospective review","volume":"12","author":"Wichman","year":"2009","journal-title":"Arch women\u2019s Ment Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e003062","DOI":"10.1136\/bmjopen-2013-003062","article-title":"Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study","volume":"3","author":"Sadowski","year":"2013","journal-title":"BMJ Open"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1002\/pds.3749","article-title":"Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study","volume":"24","author":"Bellet","year":"2015","journal-title":"Pharmacoepidemiology Drug Safety"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2298","article-title":"Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study","volume":"350","author":"Vigod","year":"2015","journal-title":"bmj"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.07.023","article-title":"Risks associated with antipsychotic treatment in pregnancy: comparative cohort studies based on electronic health records","volume":"176","author":"Petersen","year":"2016","journal-title":"Schizophr Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/0091217417696739","article-title":"Atypical antipsychotic use and outcomes in an urban maternal mental health service","volume":"51","author":"Hatters Friedman","year":"2016","journal-title":"Int J Psychiatry Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jpsychires.2017.07.025","article-title":"Use of atypical antipsychotics in pregnancy and maternal gestational diabetes","volume":"95","author":"Panchaud","year":"2017","journal-title":"J Psychiatr Res"},{"key":"B17","article-title":"The effects of gestational use of antidepressants and antipsychotics on neonatal outcomes for women with severe mental illness","volume":"57","author":"Frayne","year":"2017","journal-title":"Aust New Z J Obstetrics Gynaecology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17040393","article-title":"Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes","volume":"175","author":"Park","year":"2018","journal-title":"Am J Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02769-z","article-title":"Second-generation antipsychotics and pregnancy complications","volume":"76","author":"Ellfolk","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00908-2","article-title":"Antipsychotic use during pregnancy and risk for gestational diabetes: a national register-based cohort study in Sweden","volume":"36","author":"Heinonen","year":"2022","journal-title":"CNS Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/08039488.2023.2205852","article-title":"Quetiapine and other antipsychotic medications during pregnancy: a 15-year follow-up of a university hospital birth register","volume":"77","author":"Kananen","year":"2023","journal-title":"Nordic J Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.01.030","article-title":"The use of first and second-generation antipsychotic drugs and the potential to develop gestational diabetes mellitus among perinatal patients with psychosis","volume":"254","author":"Kulkarni","year":"2023","journal-title":"Schizophr Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"sbae132","DOI":"10.1093\/schbul\/sbae132","article-title":"Clozapine safety in pregnancy: A clinical study","author":"Kulkarni","year":"2024","journal-title":"Schizophr Bull"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ps.201600408","article-title":"Antipsychotic medication use among publicly insured pregnant women in the United States","volume":"68","author":"Park","year":"2017","journal-title":"Psychiatr Serv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.815456","article-title":"Understanding the effects of antipsychotics on appetite control","volume":"8","author":"Mukherjee","year":"2022","journal-title":"Front Nutr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.3390\/ijms26052320","article-title":"Unveiling gestational diabetes: an overview of pathophysiology and management","volume":"26","author":"Mittal","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.schres.2020.11.021","article-title":"Association between antipsychotic use in pregnancy and the risk of gestational diabetes: Population-based cohort studies from the United Kingdom and Hong Kong and an updated meta-analysis","volume":"229","author":"Wang","year":"2021","journal-title":"Schizophr Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2022.04.006","article-title":"Antipsychotic use in early pregnancy and the risk of maternal and neonatal complications","volume":"97","author":"Lin","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2017.09.002","article-title":"Gestational weight gain and pre-pregnancy body mass index associated with second-generation antipsychotic drug use during pregnancy","volume":"59","author":"Freeman","year":"2018","journal-title":"Psychosomatics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2020.03.048","article-title":"Antipsychotic drug use in pregnancy: A multinational study from ten countries","volume":"220","author":"Reutfors","year":"2020","journal-title":"Schizophr Res"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1710101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:10:21Z","timestamp":1770729021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1710101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":30,"alternative-id":["10.3389\/fpsyt.2025.1710101"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1710101","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"1710101"}}